Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children

International Journal of Epidemiology

Volumn 38, Issue 6, 2009, Pages 1612-1621

  Edmonds, Andrew ^a   Lusiama, Jean ^b   Napravnik, Sonia ^a,c   Kitetele, Faustin ^c   Van Rie, Annelies ^a   Behets, Frieda ^a,c  

^a IL   (United States)

^b UNIVERSITY OF KINSHASA   (Congo)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anti retroviral therapy; Children; HIV; Marginal structural model; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

CHILD HEALTH; COHORT ANALYSIS; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; NUMERICAL MODEL; TUBERCULOSIS;

ARTICLE; CHILD; COHORT ANALYSIS; CONGO; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDEMIC DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; CD4 LYMPHOCYTE COUNT; DEMOCRATIC REPUBLIC CONGO; FOLLOW UP; IMMUNOLOGY; MICROBIOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; VIRUS LOAD;

DEMOCRATIC REPUBLIC CONGO; KINSHASA; VILLE DE KINSHASA;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEMOCRATIC REPUBLIC OF THE CONGO; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TUBERCULOSIS; VIRAL LOAD;

EID: 75349085407     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp208     Document Type: Article

References (42)

1. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003;301:1535-37.
2. World Health Organization. Recommendations of the Interim Policy on Collaborative TB/HIV activities. Wkly Epidemiol Rec 2004;79:6-11.
3. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005;191:150-8.
4. Yazdanpanah Y, Chene G, Losina E et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001;30:864-71.
5. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-16.
6. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-64.
7. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000;4: 1026-31.
8. Miranda A, Morgan M, Jamal L et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2007;2:e826.
9. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002;2:93-102.
10. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. J Am Med Assoc 2007;298:1888-99.
11. Kouakoussui A, Fassinou P, Anaky MF et al. Respiratory manifestations in HIV-infected children pre- and post-HAART in Abidjan, the Ivory Coast. Paediatr Respir Rev 2004;5:311-15.
12. Martinson N, Moultrieh H, Barry G et al. Incidence of Tuberculosis in HIV-infected Children: The Influence of HAART [Abstract 22]. 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, 2006.
13. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr 2008;8:1.
14. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach - 2006 rev. Geneva: World Health Organization, 2006.
15. World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach. Geneva: World Health Organization, 2007.
16. National Program for the Fight Against AIDS. National Guide for Antiretroviral Treatment of HIV Infection. Kinshasa: Ministry of Health, 2005.
17. Edwards K. The diagnosis of childhood tuberculosis. P N G Med J. 1987 Jun;30:169-78.
18. Berhane R, Bagenda D, Marum L et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics 1997;100:E7.
19. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE, Jr. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J 2003;22:1033-39.
20. Centers for Disease Control and Prevention. 2000 CDC Growth Charts: United States. Available at: www.cdc.gov/growthcharts (1 July 2008, date last accessed).
21. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37-48.
22. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60.
23. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11: 561-70.
24. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-73.
25. Fairall LR, Bachmann MO, Louwagie GM et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86-93.
26. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005;19:1113-24.
27. Kampmann B, Tena-Coki GN, Nicol MP, Levin M, Eley B. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS 2006;20: 1011-18.
28. Di Perri G, Cruciani M, Danzi MC et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;2:1502-4.
29. Lawn SD, Badri M, Wood R. Tuberculosis among HIVinfected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-16.
30. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N. The burden of childhood tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis 2006;10:259-63.
31. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004;8:636-47.
32. Sutherland R, Yang H, Scriba TJ et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigenspecific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006;20:821-29.
33. Zar HJ, Cotton MF, Strauss S et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Br Med J 2007;334:136.
34. Westreich D, Sanne I, Maskew M et al. Tuberculosis Treatment and Risk of Stavudine Toxicity in Johannesburg [Abstract]. 39th Union World Conference on Lung Health, Paris, France, 2008.
35. Eshleman SH, Mracna M, Guay LA et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-57.
36. Flys T, Nissley DV, Claasen CW et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-29.
37. Behets FM, Matendo R, Vaz LM et al. Preventing vertical transmission of HIV in Kinshasa, Democratic Republic of the Congo: a baseline survey of 18 antenatal clinics. Bull World Health Organ 2006;84:969-75.
38. Elenga N, Kouakoussui KA, Bonard D et al. Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Cote d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J 2005; 24:1077-82.
39. Enarson PM, Enarson DA, Gie R. Management of tuberculosis in children in low-income countries. Int J Tuberc Lung Dis 2005;9:1299-304.
40. Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006;100:415-31.
41. Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006;10:946-53.
42. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2006;25:53-58.